Fortitude Family Office’s Theravance Biopharma TBPH Stock Holding History

Fortitude Family Office’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69K	Hold	158	–	–	﹤0.01%	1359
2026 Q1	$2.56K	Hold	158	–	–	﹤0.01%	1198
2025 Q4	$2.96K	Hold	158	–	–	﹤0.01%	1014
2025 Q3	$2.31K	Hold	158	–	–	﹤0.01%	1155
2025 Q2	$1.74K	Sell	158 -19	-11%	-$185	﹤0.01%	1267
2025 Q1	$1.58K	Hold	177	–	–	﹤0.01%	957
2024 Q4	$1.67K	Buy	+177	New	+$1.61K	﹤0.01%	1062
2024 Q1	–	Sell	-441	Closed	-$4.96K	–	1079
2023 Q4	$4.96K	Buy	+441	New	+$4.44K	﹤0.01%	641

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fortitude Family Office's TBPH Position: Q2 2026 in Review

Fortitude Family Office held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 158 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Fortitude Family Office first reported a position in TBPH in Q4 2023 and has held it in 8 quarters since. The position peaked at $4.96K in Q4 2023. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Fortitude Family Office held 158 shares of Theravance Biopharma worth $2.69K as of Q2 2026.
Fortitude Family Office left its Theravance Biopharma share count unchanged in Q2 2026.
Theravance Biopharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1359 holding.
Fortitude Family Office first reported a position in Theravance Biopharma in Q4 2023 and has held it in 8 quarters since.
Fortitude Family Office's Theravance Biopharma position peaked at $4.96K in Q4 2023.
180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.